MovDisordV3, PascalFrancis, Corpus, bibRecord, 000914

Impaired Insulin Sensitivity and Secretion in Normoglycemic Patients with Spinocerebellar Ataxia Type 1

Identifieur interne : 000914 ( PascalFrancis/Corpus ); précédent : 000913; suivant : 000915

Impaired Insulin Sensitivity and Secretion in Normoglycemic Patients with Spinocerebellar Ataxia Type 1

Auteurs : Nebojša M. Lalic ; Nataša Dragasevic ; Elka Stefanova ; Aleksandra Jotic ; Katarina Lalic ; Tanja Milicic ; Igor Petrovic ; Marija Macesic ; Vladimir S. Kostic

Source :

Movement disorders [ 0885-3185 ] ; 2010.

RBID : Pascal:10-0446317

Descripteurs français

Pascal (Inist)
- Insulinorésistance, Pathologie du système nerveux, Insuline, Sensibilité, Homme, Ataxie spinocérébelleuse.

English descriptors

KwdEn :
- Human, Insulin, Insulin resistance, Nervous system diseases, Sensitivity, Spinocerebellar ataxia.

Abstract

We have recently shown an impairment in insulin sensitivity and insulin secretion in normoglycemic patients with Huntington disease (HD). To investigate whether such observations are HD-specific or may be common to other polyglutamine diseases, glucose homeostasis was studied in 12 unrelated, untreated normoglycemic patients with spinocerebellar ataxia type 1 (SCA1), another entity from the family of polyglutamine diseases, and 24 healthy, matched controls. Metabolic investigations included (a) glucose tolerance assessment on the basis of glucose curve during oral glucose challenge; (b) insulin sensitivity assessment by the homeostasis model assessment (HOMA) and the euglycemic insulin clamp (M value); and (c) insulin secretion by acute insulin response (AIR) and insulinogenic index. The evaluation of insulin sensitivity demonstrated higher HOMA-insulin resistance indices, and lower M values (P < 0.001 and P < 0.05, respectively), while both the AIR and the insulinogenic index were lower in patients with SCA1 compared to controls (P < 0.001 and P < 0.05, respectively). Our data suggested an impairment in insulin secretion capacity, as well as simultaneous decrease in insulin sensitivity, with an increase in insulin resistance level in patients with SCA1.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 25`
A06				`@2 12`
A08	`01`	`1`	`ENG`	`@1 Impaired Insulin Sensitivity and Secretion in Normoglycemic Patients with Spinocerebellar Ataxia Type 1`
A11	`01`	`1`		`@1 LALIC (Nebojša M.)`
A11	`02`	`1`		`@1 DRAGASEVIC (Nataša)`
A11	`03`	`1`		`@1 STEFANOVA (Elka)`
A11	`04`	`1`		`@1 JOTIC (Aleksandra)`
A11	`05`	`1`		`@1 LALIC (Katarina)`
A11	`06`	`1`		`@1 MILICIC (Tanja)`
A11	`07`	`1`		`@1 PETROVIC (Igor)`
A11	`08`	`1`		`@1 MACESIC (Marija)`
A11	`09`	`1`		`@1 KOSTIC (Vladimir S.)`
A14	`01`			`@1 Clinical Center of Serbia, Institute for Endocrinology, Diabetes and Metabolic Diseases @2 Belgrade @3 SRB @Z 1 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 8 aut.`
A14	`02`			`@1 Clinical Center of Serbia, Institute of Neurology @2 Belgrade @3 SRB @Z 2 aut. @Z 3 aut. @Z 7 aut. @Z 9 aut.`
A20				`@1 1976-1980`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000194841700290`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 13 ref.`
A47	`01`	`1`		`@0 10-0446317`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 We have recently shown an impairment in insulin sensitivity and insulin secretion in normoglycemic patients with Huntington disease (HD). To investigate whether such observations are HD-specific or may be common to other polyglutamine diseases, glucose homeostasis was studied in 12 unrelated, untreated normoglycemic patients with spinocerebellar ataxia type 1 (SCA1), another entity from the family of polyglutamine diseases, and 24 healthy, matched controls. Metabolic investigations included (a) glucose tolerance assessment on the basis of glucose curve during oral glucose challenge; (b) insulin sensitivity assessment by the homeostasis model assessment (HOMA) and the euglycemic insulin clamp (M value); and (c) insulin secretion by acute insulin response (AIR) and insulinogenic index. The evaluation of insulin sensitivity demonstrated higher HOMA-insulin resistance indices, and lower M values (P < 0.001 and P < 0.05, respectively), while both the AIR and the insulinogenic index were lower in patients with SCA1 compared to controls (P < 0.001 and P < 0.05, respectively). Our data suggested an impairment in insulin secretion capacity, as well as simultaneous decrease in insulin sensitivity, with an increase in insulin resistance level in patients with SCA1.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17F`
C03	`01`	`X`	`FRE`	`@0 Insulinorésistance @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Insulin resistance @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Resistancia insulina @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Insuline @5 09`
C03	`03`	`X`	`ENG`	`@0 Insulin @5 09`
C03	`03`	`X`	`SPA`	`@0 Insulina @5 09`
C03	`04`	`X`	`FRE`	`@0 Sensibilité @5 10`
C03	`04`	`X`	`ENG`	`@0 Sensitivity @5 10`
C03	`04`	`X`	`SPA`	`@0 Sensibilidad @5 10`
C03	`05`	`X`	`FRE`	`@0 Homme @5 11`
C03	`05`	`X`	`ENG`	`@0 Human @5 11`
C03	`05`	`X`	`SPA`	`@0 Hombre @5 11`
C03	`06`	`X`	`FRE`	`@0 Ataxie spinocérébelleuse @2 NM @5 12`
C03	`06`	`X`	`ENG`	`@0 Spinocerebellar ataxia @2 NM @5 12`
C03	`06`	`X`	`SPA`	`@0 Ataxia spinocerebelosa @2 NM @5 12`
C07	`01`	`X`	`FRE`	`@0 Hormone pancréatique @5 37`
C07	`01`	`X`	`ENG`	`@0 Pancreatic hormone @5 37`
C07	`01`	`X`	`SPA`	`@0 Hormona pancreática @5 37`
C07	`02`	`X`	`FRE`	`@0 Maladie dégénérative @5 38`
C07	`02`	`X`	`ENG`	`@0 Degenerative disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie héréditaire @5 39`
C07	`03`	`X`	`ENG`	`@0 Genetic disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad hereditaria @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Endocrinopathie @5 42`
C07	`05`	`X`	`ENG`	`@0 Endocrinopathy @5 42`
C07	`05`	`X`	`SPA`	`@0 Endocrinopatía @5 42`
C07	`06`	`X`	`FRE`	`@0 Maladie métabolique @5 43`
C07	`06`	`X`	`ENG`	`@0 Metabolic diseases @5 43`
C07	`06`	`X`	`SPA`	`@0 Metabolismo patología @5 43`
C07	`07`	`X`	`FRE`	`@0 Résistance tissu cible @5 44`
C07	`07`	`X`	`ENG`	`@0 Target tissue resistance @5 44`
C07	`07`	`X`	`SPA`	`@0 Resistencia tejido blanco @5 44`
N21				`@1 291`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 10-0446317 INIST
ET :	Impaired Insulin Sensitivity and Secretion in Normoglycemic Patients with Spinocerebellar Ataxia Type 1
AU :	LALIC (Nebojša M.); DRAGASEVIC (Nataša); STEFANOVA (Elka); JOTIC (Aleksandra); LALIC (Katarina); MILICIC (Tanja); PETROVIC (Igor); MACESIC (Marija); KOSTIC (Vladimir S.)
AF :	Clinical Center of Serbia, Institute for Endocrinology, Diabetes and Metabolic Diseases/Belgrade/Serbie (1 aut., 4 aut., 5 aut., 6 aut., 8 aut.); Clinical Center of Serbia, Institute of Neurology/Belgrade/Serbie (2 aut., 3 aut., 7 aut., 9 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 12; Pp. 1976-1980; Bibl. 13 ref.
LA :	Anglais
EA :	We have recently shown an impairment in insulin sensitivity and insulin secretion in normoglycemic patients with Huntington disease (HD). To investigate whether such observations are HD-specific or may be common to other polyglutamine diseases, glucose homeostasis was studied in 12 unrelated, untreated normoglycemic patients with spinocerebellar ataxia type 1 (SCA1), another entity from the family of polyglutamine diseases, and 24 healthy, matched controls. Metabolic investigations included (a) glucose tolerance assessment on the basis of glucose curve during oral glucose challenge; (b) insulin sensitivity assessment by the homeostasis model assessment (HOMA) and the euglycemic insulin clamp (M value); and (c) insulin secretion by acute insulin response (AIR) and insulinogenic index. The evaluation of insulin sensitivity demonstrated higher HOMA-insulin resistance indices, and lower M values (P < 0.001 and P < 0.05, respectively), while both the AIR and the insulinogenic index were lower in patients with SCA1 compared to controls (P < 0.001 and P < 0.05, respectively). Our data suggested an impairment in insulin secretion capacity, as well as simultaneous decrease in insulin sensitivity, with an increase in insulin resistance level in patients with SCA1.
CC :	002B17; 002B17F
FD :	Insulinorésistance; Pathologie du système nerveux; Insuline; Sensibilité; Homme; Ataxie spinocérébelleuse
FG :	Hormone pancréatique; Maladie dégénérative; Maladie héréditaire; Pathologie du système nerveux central; Endocrinopathie; Maladie métabolique; Résistance tissu cible
ED :	Insulin resistance; Nervous system diseases; Insulin; Sensitivity; Human; Spinocerebellar ataxia
EG :	Pancreatic hormone; Degenerative disease; Genetic disease; Central nervous system disease; Endocrinopathy; Metabolic diseases; Target tissue resistance
SD :	Resistancia insulina; Sistema nervioso patología; Insulina; Sensibilidad; Hombre; Ataxia spinocerebelosa
LO :	INIST-20953.354000194841700290
ID :	10-0446317

Links to Exploration step

Pascal:10-0446317

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Impaired Insulin Sensitivity and Secretion in Normoglycemic Patients with Spinocerebellar Ataxia Type 1</title>
<author><name sortKey="Lalic, Nebojsa M" sort="Lalic, Nebojsa M" uniqKey="Lalic N" first="Nebojša M." last="Lalic">Nebojša M. Lalic</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Center of Serbia, Institute for Endocrinology, Diabetes and Metabolic Diseases</s1>
<s2>Belgrade</s2>
<s3>SRB</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dragasevic, Natasa" sort="Dragasevic, Natasa" uniqKey="Dragasevic N" first="Nataša" last="Dragasevic">Nataša Dragasevic</name>
<affiliation><inist:fA14 i1="02"><s1>Clinical Center of Serbia, Institute of Neurology</s1>
<s2>Belgrade</s2>
<s3>SRB</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stefanova, Elka" sort="Stefanova, Elka" uniqKey="Stefanova E" first="Elka" last="Stefanova">Elka Stefanova</name>
<affiliation><inist:fA14 i1="02"><s1>Clinical Center of Serbia, Institute of Neurology</s1>
<s2>Belgrade</s2>
<s3>SRB</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jotic, Aleksandra" sort="Jotic, Aleksandra" uniqKey="Jotic A" first="Aleksandra" last="Jotic">Aleksandra Jotic</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Center of Serbia, Institute for Endocrinology, Diabetes and Metabolic Diseases</s1>
<s2>Belgrade</s2>
<s3>SRB</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lalic, Katarina" sort="Lalic, Katarina" uniqKey="Lalic K" first="Katarina" last="Lalic">Katarina Lalic</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Center of Serbia, Institute for Endocrinology, Diabetes and Metabolic Diseases</s1>
<s2>Belgrade</s2>
<s3>SRB</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Milicic, Tanja" sort="Milicic, Tanja" uniqKey="Milicic T" first="Tanja" last="Milicic">Tanja Milicic</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Center of Serbia, Institute for Endocrinology, Diabetes and Metabolic Diseases</s1>
<s2>Belgrade</s2>
<s3>SRB</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Petrovic, Igor" sort="Petrovic, Igor" uniqKey="Petrovic I" first="Igor" last="Petrovic">Igor Petrovic</name>
<affiliation><inist:fA14 i1="02"><s1>Clinical Center of Serbia, Institute of Neurology</s1>
<s2>Belgrade</s2>
<s3>SRB</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Macesic, Marija" sort="Macesic, Marija" uniqKey="Macesic M" first="Marija" last="Macesic">Marija Macesic</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Center of Serbia, Institute for Endocrinology, Diabetes and Metabolic Diseases</s1>
<s2>Belgrade</s2>
<s3>SRB</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kostic, Vladimir S" sort="Kostic, Vladimir S" uniqKey="Kostic V" first="Vladimir S." last="Kostic">Vladimir S. Kostic</name>
<affiliation><inist:fA14 i1="02"><s1>Clinical Center of Serbia, Institute of Neurology</s1>
<s2>Belgrade</s2>
<s3>SRB</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0446317</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0446317 INIST</idno>
<idno type="RBID">Pascal:10-0446317</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000914</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Impaired Insulin Sensitivity and Secretion in Normoglycemic Patients with Spinocerebellar Ataxia Type 1</title>
<author><name sortKey="Lalic, Nebojsa M" sort="Lalic, Nebojsa M" uniqKey="Lalic N" first="Nebojša M." last="Lalic">Nebojša M. Lalic</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Center of Serbia, Institute for Endocrinology, Diabetes and Metabolic Diseases</s1>
<s2>Belgrade</s2>
<s3>SRB</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dragasevic, Natasa" sort="Dragasevic, Natasa" uniqKey="Dragasevic N" first="Nataša" last="Dragasevic">Nataša Dragasevic</name>
<affiliation><inist:fA14 i1="02"><s1>Clinical Center of Serbia, Institute of Neurology</s1>
<s2>Belgrade</s2>
<s3>SRB</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stefanova, Elka" sort="Stefanova, Elka" uniqKey="Stefanova E" first="Elka" last="Stefanova">Elka Stefanova</name>
<affiliation><inist:fA14 i1="02"><s1>Clinical Center of Serbia, Institute of Neurology</s1>
<s2>Belgrade</s2>
<s3>SRB</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jotic, Aleksandra" sort="Jotic, Aleksandra" uniqKey="Jotic A" first="Aleksandra" last="Jotic">Aleksandra Jotic</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Center of Serbia, Institute for Endocrinology, Diabetes and Metabolic Diseases</s1>
<s2>Belgrade</s2>
<s3>SRB</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lalic, Katarina" sort="Lalic, Katarina" uniqKey="Lalic K" first="Katarina" last="Lalic">Katarina Lalic</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Center of Serbia, Institute for Endocrinology, Diabetes and Metabolic Diseases</s1>
<s2>Belgrade</s2>
<s3>SRB</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Milicic, Tanja" sort="Milicic, Tanja" uniqKey="Milicic T" first="Tanja" last="Milicic">Tanja Milicic</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Center of Serbia, Institute for Endocrinology, Diabetes and Metabolic Diseases</s1>
<s2>Belgrade</s2>
<s3>SRB</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Petrovic, Igor" sort="Petrovic, Igor" uniqKey="Petrovic I" first="Igor" last="Petrovic">Igor Petrovic</name>
<affiliation><inist:fA14 i1="02"><s1>Clinical Center of Serbia, Institute of Neurology</s1>
<s2>Belgrade</s2>
<s3>SRB</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Macesic, Marija" sort="Macesic, Marija" uniqKey="Macesic M" first="Marija" last="Macesic">Marija Macesic</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Center of Serbia, Institute for Endocrinology, Diabetes and Metabolic Diseases</s1>
<s2>Belgrade</s2>
<s3>SRB</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kostic, Vladimir S" sort="Kostic, Vladimir S" uniqKey="Kostic V" first="Vladimir S." last="Kostic">Vladimir S. Kostic</name>
<affiliation><inist:fA14 i1="02"><s1>Clinical Center of Serbia, Institute of Neurology</s1>
<s2>Belgrade</s2>
<s3>SRB</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Human</term>
<term>Insulin</term>
<term>Insulin resistance</term>
<term>Nervous system diseases</term>
<term>Sensitivity</term>
<term>Spinocerebellar ataxia</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Insulinorésistance</term>
<term>Pathologie du   système nerveux</term>
<term>Insuline</term>
<term>Sensibilité</term>
<term>Homme</term>
<term>Ataxie spinocérébelleuse</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We have recently shown an impairment in insulin sensitivity and insulin secretion in normoglycemic patients with Huntington disease (HD). To investigate whether such observations are HD-specific or may be common to other polyglutamine diseases, glucose homeostasis was studied in 12 unrelated, untreated normoglycemic patients with spinocerebellar ataxia type 1 (SCA1), another entity from the family of polyglutamine diseases, and 24 healthy, matched controls. Metabolic investigations included (a) glucose tolerance assessment on the basis of glucose curve during oral glucose challenge; (b) insulin sensitivity assessment by the homeostasis model assessment (HOMA) and the euglycemic insulin clamp (M value); and (c) insulin secretion by acute insulin response (AIR) and insulinogenic index. The evaluation of insulin sensitivity demonstrated higher HOMA-insulin resistance indices, and lower M values (P < 0.001 and P < 0.05, respectively), while both the AIR and the insulinogenic index were lower in patients with SCA1 compared to controls (P < 0.001 and P < 0.05, respectively). Our data suggested an impairment in insulin secretion capacity, as well as simultaneous decrease in insulin sensitivity, with an increase in insulin resistance level in patients with SCA1.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>25</s2>
</fA05>
<fA06><s2>12</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Impaired Insulin Sensitivity and Secretion in Normoglycemic Patients with Spinocerebellar Ataxia Type 1</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>LALIC (Nebojša M.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>DRAGASEVIC (Nataša)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>STEFANOVA (Elka)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>JOTIC (Aleksandra)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>LALIC (Katarina)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MILICIC (Tanja)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>PETROVIC (Igor)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>MACESIC (Marija)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>KOSTIC (Vladimir S.)</s1>
</fA11>
<fA14 i1="01"><s1>Clinical Center of Serbia, Institute for Endocrinology, Diabetes and Metabolic Diseases</s1>
<s2>Belgrade</s2>
<s3>SRB</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Clinical Center of Serbia, Institute of Neurology</s1>
<s2>Belgrade</s2>
<s3>SRB</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s1>1976-1980</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000194841700290</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>13 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0446317</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We have recently shown an impairment in insulin sensitivity and insulin secretion in normoglycemic patients with Huntington disease (HD). To investigate whether such observations are HD-specific or may be common to other polyglutamine diseases, glucose homeostasis was studied in 12 unrelated, untreated normoglycemic patients with spinocerebellar ataxia type 1 (SCA1), another entity from the family of polyglutamine diseases, and 24 healthy, matched controls. Metabolic investigations included (a) glucose tolerance assessment on the basis of glucose curve during oral glucose challenge; (b) insulin sensitivity assessment by the homeostasis model assessment (HOMA) and the euglycemic insulin clamp (M value); and (c) insulin secretion by acute insulin response (AIR) and insulinogenic index. The evaluation of insulin sensitivity demonstrated higher HOMA-insulin resistance indices, and lower M values (P < 0.001 and P < 0.05, respectively), while both the AIR and the insulinogenic index were lower in patients with SCA1 compared to controls (P < 0.001 and P < 0.05, respectively). Our data suggested an impairment in insulin secretion capacity, as well as simultaneous decrease in insulin sensitivity, with an increase in insulin resistance level in patients with SCA1.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17F</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Insulinorésistance</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Insulin resistance</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Resistancia insulina</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Insuline</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Insulin</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Insulina</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Sensibilité</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Sensitivity</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Sensibilidad</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Homme</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Human</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Hombre</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Ataxie spinocérébelleuse</s0>
<s2>NM</s2>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Spinocerebellar ataxia</s0>
<s2>NM</s2>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Ataxia spinocerebelosa</s0>
<s2>NM</s2>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Hormone pancréatique</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Pancreatic hormone</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hormona pancreática</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie héréditaire</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Genetic disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad hereditaria</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Endocrinopathie</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Endocrinopathy</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Endocrinopatía</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Maladie métabolique</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Metabolic diseases</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Metabolismo patología</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Résistance tissu cible</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Target tissue resistance</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Resistencia tejido blanco</s0>
<s5>44</s5>
</fC07>
<fN21><s1>291</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 10-0446317 INIST</NO>
<ET>Impaired Insulin Sensitivity and Secretion in Normoglycemic Patients with Spinocerebellar Ataxia Type 1</ET>
<AU>LALIC (Nebojša M.); DRAGASEVIC (Nataša); STEFANOVA (Elka); JOTIC (Aleksandra); LALIC (Katarina); MILICIC (Tanja); PETROVIC (Igor); MACESIC (Marija); KOSTIC (Vladimir S.)</AU>
<AF>Clinical Center of Serbia, Institute for Endocrinology, Diabetes and Metabolic Diseases/Belgrade/Serbie (1 aut., 4 aut., 5 aut., 6 aut., 8 aut.); Clinical Center of Serbia, Institute of Neurology/Belgrade/Serbie (2 aut., 3 aut., 7 aut., 9 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 12; Pp. 1976-1980; Bibl. 13 ref.</SO>
<LA>Anglais</LA>
<EA>We have recently shown an impairment in insulin sensitivity and insulin secretion in normoglycemic patients with Huntington disease (HD). To investigate whether such observations are HD-specific or may be common to other polyglutamine diseases, glucose homeostasis was studied in 12 unrelated, untreated normoglycemic patients with spinocerebellar ataxia type 1 (SCA1), another entity from the family of polyglutamine diseases, and 24 healthy, matched controls. Metabolic investigations included (a) glucose tolerance assessment on the basis of glucose curve during oral glucose challenge; (b) insulin sensitivity assessment by the homeostasis model assessment (HOMA) and the euglycemic insulin clamp (M value); and (c) insulin secretion by acute insulin response (AIR) and insulinogenic index. The evaluation of insulin sensitivity demonstrated higher HOMA-insulin resistance indices, and lower M values (P < 0.001 and P < 0.05, respectively), while both the AIR and the insulinogenic index were lower in patients with SCA1 compared to controls (P < 0.001 and P < 0.05, respectively). Our data suggested an impairment in insulin secretion capacity, as well as simultaneous decrease in insulin sensitivity, with an increase in insulin resistance level in patients with SCA1.</EA>
<CC>002B17; 002B17F</CC>
<FD>Insulinorésistance; Pathologie du   système nerveux; Insuline; Sensibilité; Homme; Ataxie spinocérébelleuse</FD>
<FG>Hormone pancréatique; Maladie dégénérative; Maladie héréditaire; Pathologie du   système nerveux central; Endocrinopathie; Maladie métabolique; Résistance tissu cible</FG>
<ED>Insulin resistance; Nervous system diseases; Insulin; Sensitivity; Human; Spinocerebellar ataxia</ED>
<EG>Pancreatic hormone; Degenerative disease; Genetic disease; Central nervous system disease; Endocrinopathy; Metabolic diseases; Target tissue resistance</EG>
<SD>Resistancia insulina; Sistema nervioso patología; Insulina; Sensibilidad; Hombre; Ataxia spinocerebelosa</SD>
<LO>INIST-20953.354000194841700290</LO>
<ID>10-0446317</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000914 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000914 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:10-0446317
   |texte=   Impaired Insulin Sensitivity and Secretion in Normoglycemic Patients with Spinocerebellar Ataxia Type 1
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Impaired Insulin Sensitivity and Secretion in Normoglycemic Patients with Spinocerebellar Ataxia Type 1

Impaired Insulin Sensitivity and Secretion in Normoglycemic Patients with Spinocerebellar Ataxia Type 1

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri